Overview

VIBATIV Pregnancy Registry

Status:
Withdrawn
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this registry is to evaluate the outcome of pregnancy in women exposed to VIBATIV at any time during pregnancy. There are no mandated physician visits for the registry.
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.
Treatments:
Telavancin